Allstate Corp Makes New $415,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)

Allstate Corp purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 1,176 shares of the biotechnology company's stock, valued at approximately $415,000.

A number of other institutional investors have also modified their holdings of UTHR. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the fourth quarter valued at approximately $25,000. Millstone Evans Group LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB boosted its position in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp grew its stake in United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in United Therapeutics in the fourth quarter worth $131,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR traded down $0.74 during midday trading on Monday, reaching $291.72. The stock had a trading volume of 626,195 shares, compared to its average volume of 451,301. The firm's 50 day moving average price is $332.23 and its 200-day moving average price is $354.12. United Therapeutics Co. has a 52 week low of $230.39 and a 52 week high of $417.82. The company has a market capitalization of $13.10 billion, a P/E ratio of 12.81, a P/E/G ratio of 0.97 and a beta of 0.63.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the company earned $4.36 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,261,606.58. This trade represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,500 shares of company stock valued at $29,502,480 over the last ninety days. Insiders own 11.90% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on UTHR shares. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.